An interventional study of Continuous Nebulization of Salbutamol and Intermittent Nebulization of Salbutamol in Asthma in Children, sponsored by Muhammad Aamir Latif. Completed at 2 sites in Pakistan. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-01-01.
Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Treatment
Asthma affects around 260 million people globally, causing around 0.5 million deaths annually. Pediatric asthma remains a major global public health challenge, significantly affecting the quality of life for many children. Therefore, this study was planned to compare the effects of continuous versus intermittent nebulization of salbutamol in the treatment of acute severe asthma (ASA) in children visiting the emergency department of a tertiary childcare hospital in South Punjab, Pakistan.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 120 is above the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →Muhammad Aamir Latif is the lead sponsor of 56 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The patients received continuous nebulization of salbutamol at a concentration of 0.3 mg/kg/hour for 4 hours, with a minimum of 5 mg/hour and a maximum of 15 mg/hour administered via high-output extended aerosol respiratory therapy (HEART).
Drug: Continuous Nebulization of Salbutamol
The patients were treated with intermittent nebulization of salbutamol at a dose of 0.15 mg/kg/dose, administered through a face mask with an oxygen flow rate of 6-8 L per minute. They received at least 2-3 nebulizations and no more than 7.5 mg/dose every 30 minutes for 4 hours.
Drug: Intermittent Nebulization of Salbutamol
Children received continuous nebulization of salbutamol at a concentration of 0.3 mg/kg/hour for 4 hours, with a minimum of 5 mg/hour and a maximum of 15 mg/hour administered via High Output Extended Aerosol Respiratory Therapy (HEART).
were treated with intermittent nebulization of salbutamol at a dose of 0.15 mg/kg/dose, administered through a face mask with an oxygen flow rate of 6-8 L per minute. They Children received at least 2-3 nebulizations and no more than 7.5 mg/dose every 30 minutes for 4 hours.
Discharge
When patients met the clinical criteria for discharge, which were an asthma score of 5 or less and a saturation level of over 94% on room air.
Time frame: 4 hours
Hospital stay
The length of stay in the hospital was calculated from admission to discharge.
Time frame: 24 hours
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muhammad Aamir Latif